Cardiff Oncology, Inc.
CRDF · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.16 | -0.75 | 0.19 | 0.00 |
| FCF Yield | -7.88% | -3.99% | -6.12% | -4.96% |
| EV / EBITDA | -11.95 | -13.62 | -13.15 | -12.57 |
| Quality | ||||
| ROIC | -24.04% | -24.71% | -19.91% | -14.88% |
| Gross Margin | 100.00% | -9,470.25% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.96 | 0.60 | 0.95 | 0.87 |
| Growth | ||||
| Revenue 3-Year CAGR | 2.89% | 9.84% | 14.18% | 21.01% |
| Free Cash Flow Growth | -29.90% | 34.70% | -24.61% | 1.81% |
| Safety | ||||
| Net Debt / EBITDA | 0.85 | 0.65 | 1.61 | 4.00 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 190.50 | 344.53 | 334.40 | 460.73 |